Press release
Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Chronic Urticaria Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Urticaria Pipeline Outlook [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Chronic Urticaria Pipeline Report
* In July 2025, Novartis Pharmaceuticals announced a study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
* DelveInsight's Chronic Urticaria Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment.
* The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.
* Promising Chronic Urticaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine , and others.
Stay ahead with the most recent pipeline outlook for Chronic Urticaria. Get insights into clinical trials, emerging therapies, and leading companies with Chronic Urticaria @ Chronic Urticaria Treatment Drugs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Urticaria Emerging Drugs Profile
* CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China's national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria.
* Povorcitinib - Incyte Corporation
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.
* Briquilimab: Jasper Therapeutics
Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.
The Chronic Urticaria Pipeline Report Provides Insights into-
* The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Urticaria with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Urticaria Treatment.
* Chronic Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chronic Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Urticaria market
Explore groundbreaking therapies and clinical trials in the Chronic Urticaria Pipeline. Access DelveInsight's detailed report now! @ New Chronic Urticaria Drugs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Urticaria Companies
Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.
Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Chronic Urticaria Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Chronic Urticaria Treatment. Learn about new drugs, Chronic Urticaria Pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Urticaria Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Chronic Urticaria Pipeline Report
* Coverage- Global
* Chronic Urticaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.
* Chronic Urticaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine , and others.
* Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Chronic Urticaria Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Urticaria Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Chronic Urticaria: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Urticaria - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
* Mid Stage Products (Phase II)
* Povorcitinib - Incyte Corporation
* Early Stage Products (Phase I)
* Briquilimab: Jasper Therapeutics
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Chronic Urticaria Key Companies
* Chronic Urticaria Key Products
* Chronic Urticaria - Unmet Needs
* Chronic Urticaria - Market Drivers and Barriers
* Chronic Urticaria - Future Perspectives and Conclusion
* Chronic Urticaria Analyst Views
* Chronic Urticaria Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-urticaria-pipeline-appears-robust-with-20-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4093257 • Views: …
More Releases from ABNewswire
Cell and Gene Therapies in Rare Disorders Market to Evolve Rapidly Over the Next …
The Key Cell and Gene Therapies in Rare Disorders Companies in the market include - REGENXBIO, Coave Therapeutics, GenSight Biologics, Ultragenyx, Pfizer, Sangamo Therapeutics, Roche, 4D Molecular Therapeutics, Astellas Gene Therapie, Actus Therapeutics, Nanoscope Therapeutics, Ocugen, jCyte, Amicus Therapeutics, Capricor Therapeutics, Nippon Shinyaku, Brainstorm Cell Therapeutics, Editas Medicine, Abeona Therapeutics, Ishin Pharma, and others.
DelveInsight's "Cell and Gene Therapies in Rare Disorders Market Insights, Epidemiology, and Market Forecast-2034 report offers an…
Cruelty.Farm: Uncovering the Truth About Animal Agriculture and Inspiring a Glob …
When it comes to the food we eat, few people stop to think about what happens before a piece of meat reaches their plate. The global food system - dominated by industrial animal agriculture - has quietly become one of the most destructive forces on the planet. From deforestation and pollution to animal suffering and public health crises, the hidden costs are immense.
This is the reality that Cruelty.Farm seeks to…
Waka Flocka Flame to Headline Nightly College Tour Launch in Austin
Waka Flocka Flame will headline the launch of the Nightly College Tour at Empire Garage in Austin, TX on November 13, 2025. The event marks Nightly's official debut in Austin and kicks off a nationwide college tour blending music, culture, and community.
Waka Flocka Flame will headline the official launch of the Nightly College Tour on Thursday, November 13, 2025 at Empire Garage in Austin, TX. The concert brings one of…
Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development …
The Key Lambert Eaton Myasthenic Syndrome Companies in the market include - Jacobus Pharmaceutical, Catalyst Pharmaceuticals, and others.
DelveInsight's "Lambert Eaton Myasthenic Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Lambert Eaton Myasthenic Syndrome, historical and forecasted epidemiology as well as the Lambert Eaton Myasthenic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
